Cell-based reparative therapies for multiple sclerosis

Current Neurology and Neuroscience Reports

Volumn 13, Issue 11, 2013, Pages

  Ben Hur, Tamir ^a,b   Fainstein, Nina ^a   Nishri, Yossi ^a  

^a Agnes Ginges Center for Human Neurogenetics   (Israel)

^b HADASSAH HEBREW UNIVERSITY MEDICAL CENTER   (Israel)

Author keywords

Cell based reparative therapies; Immunomodulation; Multiple sclerosis; Regeneration; Remyelination; Stem cells

Indexed keywords

ARTICLE; CELL DELIVERY; CELL MIGRATION; CELL POPULATION; CELL REGENERATION; CELL SURVIVAL; CELL THERAPY; CELLULAR, SUBCELLULAR AND MOLECULAR BIOLOGICAL PHENOMENA AND FUNCTIONS; CHRONIC DISEASE; CLINICAL EFFECTIVENESS; HUMAN; IMMUNOMODULATION; MESENCHYMAL STEM CELL; MULTIPLE SCLEROSIS; NERVE CELL PLASTICITY; NERVOUS SYSTEM INFLAMMATION; NEURAL STEM CELL; NONHUMAN; OLIGODENDROCYTE PRECURSOR CELL; REMYELINIZATION; STEM CELL TRANSPLANTATION; THERAPY EFFECT; ANIMAL; BIOLOGICAL THERAPY; IMMUNOLOGY; PHYSIOLOGY; PROCEDURES; TRANSPLANTATION; TRENDS; METHODOLOGY; REVIEW;

ANIMALS; CELL- AND TISSUE-BASED THERAPY; HUMANS; MULTIPLE SCLEROSIS; NEURAL STEM CELLS; NEURONAL PLASTICITY; STEM CELL TRANSPLANTATION;

EID: 84893052732     PISSN: 15284042     EISSN: 15346293     Source Type: Journal    
DOI: 10.1007/s11910-013-0397-5     Document Type: Article

References (68)

1. Politis M, Lindvall O. Clinical application of stem cell therapy in Parkinson's disease. BMC Med. 2012;10:1.
2. Precious SV, Rosser AE. Producing striatal phenotypes for transplantation in Huntington's disease. Exp BiolMed (Maywood). 2012;237: 343-51.
3. Benraiss A, Goldman SA. Cellular therapy and induced neuronal replacement for Huntington's disease. Neurotherapeutics. 2012;8: 577-90.
4. Wang S, Bates J, Li X, Schanz S, Chandler-Militello D, Levine C, et al. Human iPSC-derived oligodendrocyte progenitor cells can myelinate and rescue a mouse model of congenital hypomyelination. Cell Stem Cell. 2013;12:252-64. With this study, showing extensive migration and myelination by human OPCs in a genetic dysmyelinating mouse model with long-term mouse survival, the stage is set for clinical translation of cell therapy in human dysmyelinating diseases.
5. Zhang SC, Duncan ID. Remyelination and restoration of axonal function by glial cell transplantation. Prog Brain Res. 2000;127:515-33. (Pubitemid 35461275)
6. Blakemore WF, Franklin RJ. Transplantation options for therapeutic central nervous system remyelination. Cell Transplant. 2000;9:289-94. (Pubitemid 30252694)
7. Einstein O, Karussis D, Grigoriadis N, Mizrachi-Kol R, Reinhartz E, Abramsky O, et al. Intraventricular transplantation of neuralprecursor cell spheres attenuates acute experimental allergic encephalomyelitis. Mol Cell Neurosci. 2003;24:1074-82. (Pubitemid 38091518)
8. Pluchino S, Zanotti L, Rossi B, Brambilla E, Ottoboni L, Salani G, et al. Neurosphere-derived multipotent precursors promote neuroprotection by an immunomodulatory mechanism. Nature. 2005;436:266-71. (Pubitemid 41021278)
9. Einstein O, Fainstein N, Vaknin I, Mizrachi-Kol R, Reihartz E, Grigoriadis N, et al. Neural precursors attenuate autoimmune encephalomyelitis by peripheral immunosuppression. Ann Neurol. 2007;61: 209-18. (Pubitemid 46557345)
10. Pluchino S, Gritti A, Blezer E, Amadio S, Brambilla E, Borsellino G, et al. Human neural stem cells ameliorate autoimmune encephalomyelitis in non-human primates. Ann Neurol. 2009;66:343-54.
11. Aharonowiz M, Einstein O, Fainstein N, Lassmann H, Reubinoff B, Ben-Hur T. Neuroprotective effect of transplanted human embryonic stem cell-derived neural precursors in an animal model of multiple sclerosis. PLoS One. 2008;3:e3145.
12. Papadopoulos D, Pham-Dinh D, Reynolds R. Axon loss is responsible for chronic neurological deficit following inflammatory demyelination in the rat. Exp Neurol. 2006;197:373-85. (Pubitemid 43077145)
13. Pluchino S, Zanotti L, Brambilla E, Rovere-Querini P, Capobianco A, Alfaro-Cervello C, et al. Immune regulatory neural stem/precursor cells protect from central nervous system autoimmunity by restraining dendritic cell function. PLoS One. 2009;4:e5959.
14. Fainstein N, Vaknin I, Einstein O, Zisman P, Sasson SZ, BaniyashM, et al. Neural precursor cells inhibit multiple inflammatory signals. Mol Cell Neurosci. 2008;39:335-41.
15. Fainstein N, Einstein O, Cohen ME, Brill L, Lavon I, Ben-Hur T. Time limited immunomodulatory functions of transplanted neural precursor cells. Glia. 2013;61:140-9. This is the first study to show limitations in therapeutic plasticity of transplanted stem/precursor cells which restrict their potential in clinical translation. Essentially, transplanted neural precursor cells lose their immunomodulatoryproperties within several weeks after transplantation.
16. Einstein O, Ben-Hur T. The changing face of neural stem cell therapy in neurologic diseases. Arch Neurol. 2008;65:452-6. (Pubitemid 351549952)
17. De Feo D, Merlini A, Laterza C, Martino G. Neural stem cell transplantation in central nervous systemdisorders: fromcell replacement to neuroprotection. Curr Opin Neurol. 2012;25:322-33.
18. Ruff CA, Wilcox JT, Fehlings MG. Cell-based transplantation strategies to promote plasticity following spinal cord injury. Exp Neurol. 2012;235:78-90.
19. Hattiangady B, Shuai B, Cai J, Coksaygan T, Rao MS, Shetty AK. Increased dentate neurogenesis after grafting of glial restricted progenitors or neural stem cells in the aging hippocampus. Stem Cells. 2007;25:2104-17. (Pubitemid 47258190)
20. Ben-Shaanan TL, Ben-Hur T, Yanai J. Transplantation of neural progenitors enhances production of endogenous cells in the impaired brain. Mol Psychiatry. 2008;13:222-31.
21. Einstein O, Friedman-Levi Y, Grigoriadis N, Ben-Hur T. Transplanted neural precursors enhance host brain-derived myelin regeneration. J Neurosci. 2009;29:15694-702.
22. Uccelli A, Moretta L, Pistoia V. Mesenchymal stem cells in health and disease. Nat Rev Immunol. 2008;8:726-36.
23. Chopp M, Li Y, Zhang J. Plasticity and remodeling of brain. J Neurol Sci. 2008;265:97-101.
24. Kassis I, Vaknin-Dembinsky A, Karussis D. Bone marrow mesenchymal stem cells: Agents of immunomodulation and neuroprotection. Curr Stem Cell Res Ther. 2011;6:63-8.
25. Prineas JW, Barnard RO, Kwon EE, Sharer LR, Cho ES. Multiple sclerosis: remyelination of nascent lesions. Ann Neurol. 1993;33: 137-51. (Pubitemid 23039922)
26. Lucchinetti C, Bruck W, Parisi J, Scheithauer B, Rodriguez M, Lassmann H. Heterogeneity of multiple sclerosis lesions: implications for the pathogenesis of demyelination. Ann Neurol. 2000;47:707-17. (Pubitemid 30390191)
27. Scolding N, Franklin R, Stevens S, Heldin CH, Compston A, Newcombe J. Oligodendrocyte progenitors are present in the normal adult human CNS and in the lesions of multiple sclerosis. Brain. 1998;121:2221-8. (Pubitemid 28552461)
28. Wolswijk G. Chronic stage multiple sclerosis lesions contain a relatively quiescent population of oligodendrocyte precursor cells. J Neurosci. 1998;18:601-9. (Pubitemid 28041896)
29. Chang A, Nishiyama A, Peterson J, Prineas J, Trapp BD. NG2- positive oligodendrocyte progenitor cells in adult human brain and multiple sclerosis lesions. J Neurosci. 2000;20:6404-12.
30. Chang A, Tourtellotte WW, Rudick R, Trapp BD. Premyelinating oligodendrocytes in chronic lesions of multiple sclerosis. N Engl J Med. 2002;346:165-73. (Pubitemid 34438882)
31. Wolswijk G. Oligodendrocyte precursor cells in the demyelinated multiple sclerosis spinal cord. Brain. 2002;125:338-49. (Pubitemid 34127436)
32. Lau LW, KeoughMB, Haylock-Jacobs S, Cua R, Doring A, Sloka S, et al. Chondroitin sulfate proteoglycans in demyelinated lesions impair remyelination. Ann Neurol. 2012;72:419-32.
33. Back SA, Tuohy TM, Chen H, Wallingford N, Craig A, Struve J, et al. Hyaluronan accumulates in demyelinated lesions and inhibits oligodendrocyte progenitor maturation. Nat Med. 2005;11:966-72. (Pubitemid 41294442)
34. Sloane JA, Batt C, Ma Y, Harris ZM, Trapp B, Vartanian T. Hyaluronan blocks oligodendrocyte progenitor maturation and remyelination through TLR2. Proc Natl Acad Sci U S A. 2010;107: 11555-60. This work shows in vitro and in vivo data that provide the molecular basis by which (glial scar derived) hyaluronan inhibits remyelination.
35. Mi S, Miller RH, Lee X, ScottML, Shulag-Morskaya S, Shao Z, et al. LINGO-1 negatively regulates myelination by oligodendrocytes. Nat Neurosci. 2005;8:745-51. (Pubitemid 43085840)
36. Charles P, Hernandez MP, Stankoff B, Aigrot MS, Colin C, Rougon G, et al.Negative regulation of central nervous system myelination by polysialylated-neural cell adhesion molecule Proc Natl Acad Sci U S A. 2000;97:7585-90. (Pubitemid 30431507)
37. Charles P, Reynolds R, Seilhean D, Rougon G, Aigrot MS, Niezgoda A, et al. Re-expression of PSA-NCAM by demyelinated axons: An inhibitor of remyelination in multiple sclerosis? Brain. 2002;125: 1972-9.
38. Mi S, Hu B, Hahm K, Luo Y, Kam Hui ES, Yuan Q, et al. LINGO-1 antagonist promotes spinal cord remyelination and axonal integrity in MOG-induced experimental autoimmune encephalomyelitis. Nat Med. 2007;13:1228-33. (Pubitemid 47530642)
39. Blakemore WF, Irvine KA. Endogenous or exogenous oligodendrocytes for remyelination. J Neurol Sci. 2008;265:43-6.
40. Merkler D, Ernsting T, Kerschensteiner M, BruckW, Stadelmann C. Anewfocal EAE model of cortical demyelination:multiple sclerosislike lesions with rapid resolution of inflammation and extensive remyelination. Brain. 2006;129:1972-83. (Pubitemid 44289063)
41. Woodruff RH, Franklin RJ. Demyelination and remyelination of the caudal cerebellar peduncle of adult rats following stereotaxic injections of lysolecithin, ethidium bromide, and complement/anti-galactocerebroside: A comparative study. Glia. 1999;25:216-28. (Pubitemid 29060218)
42. Fainstein N, Cohen ME, Ben-Hur T. Time associated decline in neurotrophic properties of neural stem cell grafts render them dependent on brain region-specific environmental support. Neurobiol Dis. 2012;49C:41-8.
43. Keirstead HS, Nistor G, Bernal G, TotoiuM, Cloutier F, Sharp K, et al. Human embryonic stem cell-derived oligodendrocyte progenitor cell transplants remyelinate and restore locomotion after spinal cord injury. J Neurosci. 2005;25:4694-705. (Pubitemid 40664118)
44. Kohama I, Lankford KL, Preiningerova J, White FA, Vollmer TL, Kocsis JD. Transplantation of cryopreserved adult human Schwann cells enhances axonal conduction in demyelinated spinal cord. J Neurosci. 2001;21:944-50. (Pubitemid 32163135)
45. Sasaki M, Lankford KL, Radtke C, Honmou O, Kocsis JD. Remyelination after olfactory ensheathing cell transplantation into diverse demyelinating environments. Exp Neurol. 2011;229:88-98.
46. Zujovic V, Thibaud J, Bachelin C, Vidal M, Coulpier F, Charnay P, et al. Boundary cap cells are highly competitive for CNS remyelination: fast migration and efficient differentiation in PNS and CNS myelin-forming cells. Stem Cells. 2010;28:470-9.
47. Bai L, Lennon DP, Caplan AI, DeChant A, Hecker J, Kranso J, et al. Hepatocyte growth factor mediates mesenchymal stem cell-induced recovery in multiple sclerosis models. Nat Neurosci. 2012;15:862- 70. This study provides the (although probably not the only) molecular basis for the trophic effects of MSCs in EAE. It highlights the important unsolved question of whether treatment with beneficial mediators might be sufficient instead of the need to deliver the entire cell factory for effective therapy.
48. Fisher-Shoval Y, Barhum Y, Sadan O, Yust-Katz S, Ben-Zur T, Lev N, et al. Transplantation of placenta-derived mesenchymal stem cells in the EAE mouse model of MS. J Mol Neurosci. 2012;48:176-84.
49. Liu R, Zhang Z, Lu Z, Borlongan C, Pan J, Chen J, et al. Human umbilical cord stemcells ameliorate experimental autoimmune encephalomyelitis by regulating immunoinflammation and remyelination. Stem Cells Dev. 2013;22:1053-62.
50. Akiyama Y, Radtke C, Kocsis JD. Remyelination of the rat spinal cord by transplantation of identified bone marrow stromal cells. J Neurosci. 2002;22:6623-30. (Pubitemid 35386418)
51. Keilhoff G, Stang F, Goihl A, Wolf G, Fansa H. Transdifferentiated mesenchymal stem cells as alternative therapy in supporting nerve regeneration and myelination. Cell Mol Neurobiol. 2006;26:1235-52. (Pubitemid 44924044)
52. Keirstead HS, Ben-Hur T, Rogister B, O'LearyMT, Dubois-Dalcq M, Blakemore WF. Polysialylated neural cell adhesion moleculepositive CNS precursors generate both oligodendrocytes and Schwann cells to remyelinate the CNS after transplantation. J Neurosci. 1999;19:7529-36. (Pubitemid 29404609)
53. Ben-Hur T, Einstein O, Mizrachi-Kol R, Ben-Menachem O, Reinhartz E, Karussis D, et al. Transplanted multipotential neural precursor cells migrate into the inflamed white matter in response to experimental autoimmune encephalomyelitis. Glia. 2003;41:73-80. (Pubitemid 36164286)
54. Ben-Hur T, van Heeswijk RB, Einstein O, Aharonowiz M, Xue R, Frost EE, et al. Serial in vivo MR tracking of magnetically labeled neural spheres transplanted in chronic EAE mice. Magn Reson Med. 2007;57:164-71. (Pubitemid 46067946)
55. Muja N, Cohen ME, Zhang J, Kim H, Gilad AA, Walczak P, et al. Neural precursors exhibit distinctly different patterns of cell migration upon transplantation during either the acute or chronic phase of EAE: A serial MR imaging study. Magn Reson Med. 2011;65:1738-49.
56. Sadan O, Shemesh N, Barzilay R, Bahat-Stromza M, Melamed E, Cohen Y, et al. Migration of neurotrophic factors-secreting mesenchymal stem cells toward a quinolinic acid lesion as viewed by magnetic resonance imaging. Stem Cells. 2008;26:2542-51.
57. Grigoriadis N, Lourbopoulos A, Lagoudaki R, Frischer JM, Polyzoidou E, Touloumi O, et al. Variable behavior and complications of autologous bone marrow mesenchymal stem cells transplanted in experimental autoimmune encephalomyelitis. Exp Neurol. 2011;230:78-89.
58. Barhum Y, Gai-Castro S, Bahat-StromzaM, Barzilay R, Melamed E, OffenD. Intracerebroventricular transplantation of humanmesenchymal stem cells induced to secrete neurotrophic factors attenuates clinical symptoms in a mouse model of multiple sclerosis. J Mol Neurosci. 2010;41:129-37.
59. Yang J, Jiang Z, Fitzgerald DC, Ma C, Yu S, Li H, et al. Adult neural stem cells expressing IL-10 confer potent immunomodulation and remyelination in experimental autoimmune encephalitis. J Clin Invest. 2009;119:3678-91.
60. Sher F, Amor S, GerritsenW, Baker D, Jackson SL, Boddeke E, et al. Intraventricularly injected Olig2-NSCs attenuate established relapsing-remitting EAE in mice. Cell Transplant. 2012;21:1883-97.
61. Politi LS, BacigaluppiM, Brambilla E, CadioliM, Falini A, Comi G, et al. Magnetic-resonance-based tracking and quantification of intravenously injected neural stem cell accumulation in the brains of mice with experimental multiple sclerosis. Stem Cells. 2007;25:2583-92. (Pubitemid 47582751)
62. Borlongan CV, Glover LE, Tajiri N, Kaneko Y, Freeman TB. The great migration of bone marrow-derived stem cells toward the ischemic brain: Therapeutic implications for stroke and other neurological disorders. Prog Neurobiol. 2011;95:213-28.
63. Payne NL, Sun G, McDonald C, Layton D, Moussa L, Emerson- Webber A, et al. Distinct immunomodulatory and migratory mechanisms underpin the therapeutic potential of human mesenchymal stem cells in autoimmune demyelination. Cell Transplant. 2013;22:1409-25.
64. Bulte JW, Ben-Hur T, Miller BR, Mizrachi-Kol R, Einstein O, Reinhartz E, et al. MR microscopy of magnetically labeled neurospheres transplanted into the Lewis EAE rat brain.Magn Reson Med. 2003;50:201-5. (Pubitemid 36841877)
65. Magliozzi R, Howell O, Vora A, Serafini B, Nicholas R, Puopolo M, et al. Meningeal B-cell follicles in secondary progressive multiple sclerosis associate with early onset of disease and severe cortical pathology. Brain. 2007;130:1089-104. (Pubitemid 47355604)
66. Peters A, Pitcher LA, Sullivan JM, Mitsdoerffer M, Acton SE, Franz B, et al. Th17 cells induce ectopic lymphoid follicles in central nervous system tissue inflammation. Immunity. 2011;35:986-96. This study suggests the molecular mechanism of transition of MS pathogenesis from a systemic immunologically driven disease to a CNS-compartmentalized disease.
67. Karussis D, Karageorgiou C, Vaknin-DembinskyA, Gowda-Kurkalli B, Gomori JM, Kassis I, et al. Safety and immunological effects of mesenchymal stem cell transplantation in patients with multiple sclerosis and amyotrophic lateral sclerosis. Arch Neurol. 2010;67: 1187-94.
68. Connick P, Kolappan M, Crawley C, Webber DJ, Patani R, Michell AW, et al. Autologous mesenchymal stem cells for the treatment of secondary progressive multiple sclerosis: An open-label phase 2a proof-of-concept study. Lancet Neurol. 2012;11:150-6.